Keeble Julie Elizabeth
Centre for Integrative Biomedicine, Pharmaceutical Science Research Division, King's College London, London, UK.
Br J Pharmacol. 2009 Mar;156(5):728-9. doi: 10.1111/j.1476-5381.2008.00101.x.
Neurogenic inflammation, an important component of many disease states, is mediated by the release of neuropeptides from sensory nerves. To date, it has been possible to inhibit neurogenic inflammation using neuropeptide receptor blockers or by prevention of neuropeptide release. In the current edition of the British Journal of Pharmacology, Cattaruzza and co-workers discuss a novel way of blocking the action of neuropeptides. They have shown that the re-sensitization of the substance P neurokinin-1 receptor and the substance P-induced pro-inflammatory effects are mediated by the enzyme, endothelin-converting enzyme 1 (ECE-1). Therein, they showed that ECE-1 inhibition could prevent the re-sensitization process. This is exciting progress in our understanding of neurogenic inflammation, but it remains to be seen how inhibition of receptor recycling via ECE-1 blockade will affect other inflammatory pathways.
神经源性炎症是许多疾病状态的重要组成部分,由感觉神经释放神经肽介导。迄今为止,使用神经肽受体阻滞剂或通过防止神经肽释放来抑制神经源性炎症已成为可能。在最新一期的《英国药理学期刊》中,卡塔罗扎及其同事讨论了一种阻断神经肽作用的新方法。他们已经表明,P物质神经激肽-1受体的再敏化以及P物质诱导的促炎作用是由内皮素转换酶1(ECE-1)介导的。在该研究中,他们表明抑制ECE-1可以阻止再敏化过程。这是我们在理解神经源性炎症方面取得的令人兴奋的进展,但通过阻断ECE-1抑制受体再循环将如何影响其他炎症途径仍有待观察。